Agonistic anti-PD-1 antibodies turn on the immunosuppressive activity of PD-1
January 25, 2023
Antibodies blocking the PD-1/PD-L1 interaction are widely used to enhance immune responses against cancer. This group of antibodies binds to the membrane-distal region of the PD-1 molecule. In a recent paper published in Science Immunology, Suzuki and Tajima et al. identified another group of anti-PD-1 antibodies recognizing the membrane-proximal extracellular region of PD-1...
Checkpoint blockade to overcome acquired resistance to immunocytokine
January 18, 2023
The immunocytokine PD1-IL2v, a fusion of an anti-PD-1 antibody with an IL-2 variant that does not stimulate Treg responses, has been developed to target activation of CD8+ T cells in the tumor via PD-1 binding. Tichet and Wullschleger et al. investigated mechanisms behind intrinsic and adaptive resistance to this type of therapy in...
IL-6 blockade could enhance PD-L1 immunotherapy
January 11, 2023
In a search for potential drivers of resistance to anti-PD-L1 immunotherapy, Huseni, Wang, Klementowicz, and Yuen et al. identified IL-6 as a correlate of poor response across various tumor types in large clinical trials. To better understand how IL-6 impacts tumor control and responses to immunotherapy, the researchers analyzed several sources of clinical...